Biopharma Vital Signs

In 2026, biopharma has no shortage of scientific ambition – but the industry is also facing mounting pressure around funding, manufacturing, regulation, commercialization, and patient access

For Biopharma Vital Signs, The Medicine Maker asked industry experts for their views on the state of biotech and biopharma today. In six parts, contributors discuss the conversations shaping BIO 2026, the trends influencing development and manufacturing, the pressure points slowing progress, and the capabilities companies will need to move faster, more flexibly, and more resiliently.

The result is a snapshot of an industry in motion – one shaped by complex modalities, AI, supply chain uncertainty, shifting partnership models, and the ongoing challenge of turning innovation into therapies that can reliably reach patients.

Explore the full series below.

Biopharma Vital Signs – Part 1: Reading the Room at BIO

As BIO 2026 approaches, industry experts weigh in on the conversations likely to dominate the floor – from AI and funding pressures to manufacturing readiness, regulatory uncertainty, and the challenge of turning innovation into real-world impact.
Read the article

Biopharma Vital Signs – Part 2: Emerging Trends

Industry experts discuss the trends reshaping biotech and biopharma development – from complex modalities and manufacturing pressures to AI, funding constraints, and the growing need to plan for commercialization earlier.
Read the article